MarÃn, M.Q.; Sliepen, K.; GarcÃa-Arriaza, J.; Koekkoek, S.M.; Pérez, P.; Sorzano, C.Ó.S.; Gómez, C.E.; Sanders, R.W.; Esteban, M.
Optimized Hepatitis C Virus (HCV) E2 Glycoproteins and their Immunogenicity in Combination with MVA-HCV. Vaccines 2020, 8, 440.
https://doi.org/10.3390/vaccines8030440
AMA Style
MarÃn MQ, Sliepen K, GarcÃa-Arriaza J, Koekkoek SM, Pérez P, Sorzano CÓS, Gómez CE, Sanders RW, Esteban M.
Optimized Hepatitis C Virus (HCV) E2 Glycoproteins and their Immunogenicity in Combination with MVA-HCV. Vaccines. 2020; 8(3):440.
https://doi.org/10.3390/vaccines8030440
Chicago/Turabian Style
MarÃn, MarÃa Q., Kwinten Sliepen, Juan GarcÃa-Arriaza, Sylvie M. Koekkoek, Patricia Pérez, Carlos Óscar S. Sorzano, Carmen E. Gómez, Rogier W. Sanders, and Mariano Esteban.
2020. "Optimized Hepatitis C Virus (HCV) E2 Glycoproteins and their Immunogenicity in Combination with MVA-HCV" Vaccines 8, no. 3: 440.
https://doi.org/10.3390/vaccines8030440
APA Style
MarÃn, M. Q., Sliepen, K., GarcÃa-Arriaza, J., Koekkoek, S. M., Pérez, P., Sorzano, C. Ó. S., Gómez, C. E., Sanders, R. W., & Esteban, M.
(2020). Optimized Hepatitis C Virus (HCV) E2 Glycoproteins and their Immunogenicity in Combination with MVA-HCV. Vaccines, 8(3), 440.
https://doi.org/10.3390/vaccines8030440